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Introduction
We are living in an era of unprecedented increase in
knowledge and rapidly changing technology. This progress
in biotechnology raises complex ethical, legal, social and
religious issues. Newborn screening for detection of
congenital metabolic and endocrine disorders exists as
established programmes in most of the developed world
but its establishment in developing countries poses major
challenges as other health issues like control of infectious
diseases, malnutrition and immunization programmes take
precedence over it.
Pakistan, a developing country with an estimated
population of 167 million inhabitants, 36.3% of whom are
under 14 years of age, has as yet no newborn screening
programme at the national level. The crude birth rate is 38
to 40 per 1000 and the infant mortality rate is 80 per 1000
livebirths.1 The healthcare system is mainly hospital-based
and primary health care facilities are practically non-existing.
Here more than 80% of deliveries occur at home and 80%
of these home deliveries are usually attended by unskilled
birth attendants.2
Pakistan has a very high consanguinity rate of 46% to
61% due to strong cultural  preferences.3 As a result we face
a huge burden of inherited diseases, which contribute
significantly to the alarmingly high infant mortality rate in
Pakistan. Due to the lack of diagnostic facilities and absence
of national registries for diseases, prevalence of various
inherited diseases are not known. β thalaessemia is probably
the most common single gene disorder in our population, as
Pakistan is situated in the β thalaessemia belt4 and 5.4% of
Pakistanis are carriers for β thalaessemia.5 Other inherited
diseases more prevalent in the Pakistani community are
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G6PD deficiency and congenital hypothyroidism (CH).
Ali et al reported a G6PD deficiency frequency of 1.8%
among healthy Pakistani adults.6
Although Pakistan lacks a national programme for
newborn screening for any inherited disease, at the local
level Aga Khan University Hospital (AKUH) and few
others are doing newborn screening for CH.
We present our data on CH screening over a period of 20
years. We identified hurdles a newborn screening
programme can face in a developing country like Pakistan.
Patient and Methods
CH screening started at AKUH in March 1987. In the
first 2 years of screening all newborns delivered at AKUH
and 4 other maternity homes working under the banner of
AKUH were targeted, which included 5,000 livebirths. In
the subsequent years due to logistic reasons CH screening
was limited to babies born at AKUH only. We covered a
period of over 20 years, from 1989 to October 2008, in
which a total of 53,619 babies were screened.
Venous blood samples were collected on either the
second or third day of life. Thyroid stimulating hormone
(TSH) levels were measured by the chemiluminescence
method till 1995; afterwards the method was switched to
electro-chemiluminescence. Recall strategy (Fig. 1) was
planned if TSH was more than 13 mIU/L.
Results
In the first 2 years of CH screening between 1987 and
1988, 5,000 babies were screened and of these 5
were found to have CH, which was confirmed on the
basis of a low T4 and high TSH as has been presented by
Lakhani et al.7
For our audit we requested for medical records to provide
the number of livebirths at AKUH per year for the period
mentioned. Although we got the number of births and their
medical record numbers, it was not possible to get TSH
values of these babies through their medical records, as
these files were still not in electronic format. Also since the
TSH results usually come back after the babies are
discharged the coding was not done in the records even if
the values are found to be high.
The next option was to request neonatal TSH data from
the laboratory. We faced issues in this step as well. For the
period between 1989 and 2008, we were unable to retrieve
TSH screening results of 11,803 (22.0%) out of 53,619
babies born at AKUH. Thus screening data for only 41,816
(78.0%) babies was available for review. According to our
lab reference values babies with TSH more than 13 mIU/
L were to be recalled during the first 2 weeks of age for
repeat TSH. There was another missing link here as repeat
TSH values for the majority of babies were not available.
Among the babies whose repeat TSH was more than 13
mIU/L, 10 babies were found to have low T4 and high TSH.
None of these babies had radioisotope scanning of the
thyroid gland done, thus the etiology of CH could not be
ascertained. From January till mid-October 2008, we
carefully analysed data for each and every patient. This
period has lowest dropout rate with the highest compliance
for repeat TSH. In this period we found 2 babies with TSH
both in initial and repeat of more than 100 mIU/L. Both
babies had low free and total T4 too. Based on just this
year’s data (10 months), a mathematical estimated incidence
of CH would be about 1 in 1600 livebirths (Table 1).
Discussion
It is difficult to calculate the incidence of CH based on
our data because in 22.0% of babies first TSH values were
not available. Possible reasons for the missing records
could be that AKUH medical records were shifted from
paper to electronic and during this process some medical
records were lost. A second possibility was that some of the
babies were discharged before the second day of life when
CH screening was supposed to be done.
Most of these discharges were on parental request. Parents
were however given a lab request to get TSH screening
done as out-patient, after 3 days of age. More than 80% in
drop out rate was seen in repeat TSH, as the majority of
parents did not come for follow-up TSH when they were
recalled. Most of them probably thought that the baby had
no problems because there were no symptoms. It is possible
that among most of the babies who dropped out, some of
them had repeated their TSH at some other laboratory for
which data was not available to us. Lack of awareness
among parents was another contributing factor for not
repeating TSH levels. Also there are many private
paediatricians in city and each one not only uses differentFig. 1.  Recall strategy for elevated TSH.
TSH >13 mIU/L
Repeat TSH
TSH still >13 mIU/L
Do T4 and TSH
Low T4 and high TSH
Refer to Paediatric Endocrinologist
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In view of the issues/deficiencies that have been identified
we propose the following steps to be addressed at both
institutional and national levels.
• Designate 1 or 2 physicians, to whom laboratories will
report to regarding raised TSH values. These physicians
should then design a system where they not only inform
the patients in a timely manner, but also track the
follow-up visits.
• It is our estimate, that there are many false positives
(raised TSH) when we used the cut-off of 13 micro IU/
mL. We have reanalysed our data with a cut-off of 20
and 25 micro IU/mL, and found that our estimated recall
would be 5% and 2.3% respectively which is
significantly lower than the recall rate of 15% if the cut-
off for repeat TSH is kept at 13 mIU/L. This is close to
what other countries in the region have reported.8
• Another strategy/suggestion at the national level would
be to apply for a grant, which would provide an incentive
to get TSH repeated free of charge. In this way, we
would probably have a big enough sample size to
calculate the true incidence of CH.
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laboratories for testing, but also have different cut off
values for raised TSH.
It has been proved through decades of experience that
newborn screening saves thousands of babies from death,
mental retardation and other serious complications. It is
imperative that the importance of newborn screening
programmes is recognised by developing countries like
Pakistan and serious steps are taken at the national level to
ensure successful newborn screening for conditions like
CH, because it is easily diagnosed and the treatment is also
very cost effective when compared to the cost of care for a
mentally retarded child. Public awareness programmes
should be conducted to not only educate parents about the
consequences of CH but also to stress the need to initiate
therapy as early as possible after birth to ensure proper
brain development.
Year Total birth TSH done CH cases
n (%) detected
1989 1414 891 (63%) 1
1990 1669 776 (47%) 3
1991 1667 1400 (84%) 0
1992 1753 1554 (89%) 0
1993 1847 1700 (92%) 1
1994 1977 1701 (86%) 0
1995 2261 1680 (74%) 1
1996 2479 1976 (80%) 0
1997 2731 2114 (77%) 0
1998 2779 2403 (86%) 0
1999 2891 2296 (79%) 0
2000 2967 805 (27%) 1
2001 2909 2373 (82) 0
2002 3010 2434 (81%) 1
2003 3070 2516 (82%) 0
2004 3414 2824 (83%) 0
2005 3689 2753 (75%) 0
2006 3999 3164 (79%) 0
2007 3919 3282 (84%) 0
Jan-Oct 2008 3174 3145 (99%) 2
Total 53,619 41,816 (78.0%) 10
Table 1. CH Screening – A 20-year Audit
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